XNCR
Xencor, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website xencor.com
- Employees(FY) 281
- ISIN US98401F1057
Performance
-2.17%
1W
+21.72%
1M
-4.64%
3M
+24.22%
6M
+8.48%
YTD
-13.13%
1Y
Profile
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Investment Analysis Report: XNCR
Overview
XNCR is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $1.47 billion. In this report, we will conduct a comprehensive analysis of XNCR's financial statements over the past three years, focusing on the Balance She...
Technical Analysis of XNCR 2024-05-10
Overview:
In analyzing the technical indicators for XNCR over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the m...
Recent News & Updates
- 2024-05-11 08:02
Xencor First Quarter 2024 Earnings: Misses Expectations(Simply Wall St.)
- 2024-05-10 13:45
- 2024-05-10 06:20
- 2024-05-09 17:18
Xencor: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-09 16:09
Xencor Reports First Quarter 2024 Financial Results(Business Wire)
- 2024-05-09 11:54
- 2024-05-09 04:09
Xencor Reports First Quarter 2024 Financial Results(Businesswire)
- 2024-05-06 10:00
- 2024-05-05 22:00
- 2024-05-03 19:01
- 2024-05-02 03:31
- 2024-05-01 15:31
- 2024-04-23 20:00
XNCR: Lowering target price to $19.00(Argus Research)
- 2024-04-09 08:01
Xencor Appoints Bart Cornelissen as Chief Financial Officer(Business Wire)
- 2024-04-08 20:01
- 2024-03-08 17:01
- 2024-03-07 17:00
- 2024-02-29 05:33
Xencor Full Year 2023 Earnings: Misses Expectations(Simply Wall St.)
- 2024-02-28 16:01
Xencor to Present at Upcoming Investor Conferences(Business Wire)
- 2024-02-28 09:35
Q4 2023 Xencor Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-02-28 08:38
Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript(Insider Monkey)
- 2024-02-28 03:01
Xencor to Present at Upcoming Investor Conferences(Businesswire)
- 2024-02-27 19:38
Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript(Insidermonkey)
- 2024-02-27 17:20
- 2024-02-27 16:39
- 2024-02-27 16:26
Xencor: Q4 Earnings Snapshot(Associated Press Finance)
- 2024-02-27 16:01
- 2024-02-27 03:01
- 2024-02-20 16:31
- 2024-02-20 03:31
Page 1 of 5
previousnext